LLY•benzinga•
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight
Summary
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 31, 2025 by benzinga